Ian Krop
Associate Chief Division of Breast Oncology, Dana Farber Cancer Institute
USA
Ian Krop, MD, PhD is Associate Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, Associate Professor of Medicine at Harvard Medical School, and the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC). Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber. Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan.
